摘要
目的探究蛋白质精氨酸甲基转移酶5(PRMT5)和环氧合酶2(Cox-2)在良恶性膀胱肿瘤患者表达水平比较。方法选择来我院治疗的膀胱肿瘤患者膀胱组织83例,经过病理检测,分为良性组53例和恶性组30例,另选20例行前列腺增生症开放术中所取膀胱黏膜组织且经病理检查确定为正常的黏膜组织作为对照组,对比3组膀胱组织的PRMT5及Cox-2阳性表达率;再将恶性组按照病理分级分为低级别组11例和高级别组19例,对比2组PRMT5及Cox-2表达阳性率。结果恶性组的PRMT5及Cox-2阳性表达率明显高于良性组和对照组,且良性组也高于对照组(均P<0.05);恶性组中,高级别组PRMT5及Cox-2表达阳性率明显高于低级别组(P<0.05)。结论膀胱肿瘤恶性病变组织中PRMT5及Cox-2表达阳性率明显高于良性病变组织和正常膀胱组织,同时PRMT5及Cox-2表达阳性率与恶性病变组织病理分级及临床分期有一定关联,可以作为判断膀胱肿瘤患者病情的重要指标。
Objective To compare the expression levels of PRMT5 and Cox-2 in patients with benign and malignant bladder tumors. Methods 83 patients with bladder tumor were selected in our hospital. After pathological detection, they were divided into 53 cases of benign group and 30 cases of malignant group. Another 20 cases of bladder mucosa tissues taken during open surgery for prostatic hyperplasia and confirmed as normal by pathological examination were selected as the control group. The positive expression rates of PRMT5 and Cox-2 in the bladder tissues of the three groups were compared. The malignant group was further divided into low grade group (11 cases) and high grade group (19 cases) according to pathological classification, and the positive expression rates of PRMT5 and cox-2 in the two groups were compared. Results The positive expression rates of PRMT5 and Cox-2 in the malignant group were significantly higher than those in benign group and control group, and the benign group was also higher than the control group (P<0.05). In the malignant group, PRMT5 and Cox-2 expression positive rates in the high-level group were significantly higher than those in the low-level group (P<0.05). Conclusion The positive expression rate of PRMT5 and Cox-2 in the malignant lesion of bladder tumor was significantly higher than that in the benign lesion and normal bladder tissue. Meanwhile, the positive expression rate of PRMT5 and Cox-2 was correlated with the pathological grade and clinical stage of the malignant lesion, which could be used as an important indicator of the condition of patientswith bladder tumor.
作者
郅玲然
王卉芳
蔡凤梅
李元朋
焦向宁
ZHI Lingran;WANG Huifang;CAI Fengmei;LI Yuanpeng;JIAO Xiangning(Department of Pathology,Xi'an No.4 Hospital,Xi'an 710004,China;Department of Urology,Shaanxi Armed Police Corps Hospital,Xi'an 710054,China)
出处
《长春中医药大学学报》
2019年第6期1155-1157,共3页
Journal of Changchun University of Chinese Medicine
基金
陕西省科技计划(2005K09-G4)
西安市第四医院科研孵化基金项目(FZ-17)
